News

FierceBiotech24d
Mosaic adds to cancer combo pattern by licensing 2 clinical-stage drugs from Astex
The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...
Frontiers25d
Combinatorial biosynthesis of novel gentamicin derivatives with nonsense mutation readthrough activity and low cytotoxicity
Human embryonic kidney 293 (HEK 293) cells (CL-0001, Procell, Wuhan, China) were grown in DMEM (11996025, Gibco, Waltham, Massachusetts, United States), and the lung adenocarcinoma cell line NCI-H1299 ...
Imperial College London25d
Dr Ai Shinobu: Integrating mathematical modeling and molecular dynamics simulations to study the effect of EGFR mutations in lung cancer
Using six variants of lung cancer-derived H1299 cell lines (WT, L858R, E709G, G719S, S768I, L861Q), we conducted time-series experiments to capture molecular activity data within the EGFR pathway.
eLife1mon
Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation
(A) Co-immunoprecipitation of FLp53-FLAG, Δ133p53-FLAG, and Δ160p53-FLAG along with the FLp53-V5, Δ133p53-V5, and Δ160p53-V5 proteins in H1299 cells. The complexes were isolated with anti-FLAG ...
Frontiers2y
Tubeimoside-1: A review of its antitumor effects, pharmacokinetics, toxicity, and targeting preparations
TABLE 1. The content of TBMS-1 in herbal medicine and proprietary Chinese medicine. A systematic search of literature was performed according to the preferred reporting items for systematic reviews ...